Rhodococcus equi
๐ About
- Rhodococcus equi โ opportunistic pathogen mainly affecting immunocompromised patients (HIV/AIDS, chronic steroids, malignancy).
- Recognised zoonotic pathogen, also infects foals and other animals.
๐ฌ Characteristics
- Gram-positive, aerobic, partially acid-fast coccobacillus.
- Can be misidentified as diphtheroids (Corynebacterium-like) in labs โ needs careful recognition.
- Intracellular survival in macrophages โ contributes to chronicity.
๐ Source
- Reservoirs: Soil & animal faeces (esp. herbivores ๐ horses, cattle).
- Transmission: Inhalation of contaminated dust or direct contact with soil/animals (esp. in agricultural settings).
โ ๏ธ Pathogenicity
- Pulmonary disease:
- Cavitating pneumonia (resembles TB) with slow progression.
- Can form lung abscesses & pleural involvement.
- Disseminated infection:
- Brain abscesses ๐ง , subcutaneous abscesses, lymphadenitis.
- High mortality if untreated in immunocompromised patients.
๐ Sensitivities
- Generally sensitive to vancomycin, carbapenems, rifampicin, and fluoroquinolones.
- Combination therapy reduces relapse risk.
๐งฌ Resistance
- Resistance can emerge with prolonged/monotherapy.
- Patterns vary โ always perform susceptibility testing.
๐ฉบ Management
- Prolonged combination antibiotic therapy:
- Typical: Rifampicin + (carbapenem / fluoroquinolone / vancomycin).
- Duration: often many weeks to months, tailored to response.
- Surgical intervention: Drainage of abscesses (lung, brain, soft tissue) may be required.
- Close monitoring: Relapse risk is high in HIV/immunosuppressed patients.
โ ๏ธ Exam pearl: Rhodococcus equi causes cavitating pneumonia in HIV patients, mimicking TB, and may be misidentified as diphtheroids in labs. Requires prolonged, multi-drug therapy + sometimes surgery.